{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:57:58Z","timestamp":1777712278837,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejca.2018.06.028","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T12:54:46Z","timestamp":1532091286000},"page":"87-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1609-8113","authenticated-orcid":false,"given":"B.","family":"Bouvard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Chatelais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Souli\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Hopp\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Saulnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Capitain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Mesgouez-Nebout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Jadaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Abadie-Lacourtoisie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Campone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9972","key":"10.1016\/j.ejca.2018.06.028_bib1","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(14)62038-9","article-title":"Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)","volume":"385","author":"Allemani","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejca.2018.06.028_bib2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.ctrv.2013.03.008","article-title":"Age and the effect of physical activity on breast cancer survival: a systematic review","volume":"39","author":"Fontein","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"23","key":"10.1016\/j.ejca.2018.06.028_bib3","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-13-0838","article-title":"Metastasis dormancy in estrogen receptor-positive breast cancer","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2018.06.028_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s11914-010-0011-6","article-title":"Tumor-stromal interactions in bone metastasis","volume":"8","author":"Nannuru","year":"2010","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.028_bib5","first-page":"83","article-title":"Estrogen-deficient osteoporosis enhances the recruitment and activity of osteoclasts by breast cancer cells","volume":"31","author":"Salamanna","year":"2016","journal-title":"Histol Histopathol"},{"issue":"11","key":"10.1016\/j.ejca.2018.06.028_bib6","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-13-1246","article-title":"Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in\u00a0vivo","volume":"20","author":"Ottewell","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.ejca.2018.06.028_bib7","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1200\/JCO.2008.20.0725","article-title":"Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer","volume":"27","author":"Goodwin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10001","key":"10.1016\/j.ejca.2018.06.028_bib8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","author":"Early Breast Cancer Trialists' Collaborative","year":"2015","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.ejca.2018.06.028_bib9","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1016\/j.ejca.2007.08.029","article-title":"Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women","volume":"43","author":"McCloskey","year":"2007","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2018.06.028_bib10","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1007\/s00198-011-1870-0","article-title":"Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper","volume":"23","author":"Rizzoli","year":"2012","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1016\/j.ejca.2018.06.028_bib11","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/annonc\/mdr356","article-title":"High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy","volume":"23","author":"Bouvard","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.028_bib12","doi-asserted-by":"crossref","first-page":"djt319","DOI":"10.1093\/jnci\/djt319","article-title":"Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis","volume":"106","author":"Vera-Badillo","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.ejca.2018.06.028_bib13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00223-012-9606-5","article-title":"What is the optimal dietary intake of vitamin D for reducing fracture risk?","volume":"92","author":"Dawson-Hughes","year":"2013","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.028_bib14","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3748\/wjg.v22.i3.933","article-title":"Protective links between vitamin D, inflammatory bowel disease and colon cancer","volume":"22","author":"Meeker","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.028_bib15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.amepre.2006.11.004","article-title":"Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis","volume":"32","author":"Gorham","year":"2007","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.028_bib16","doi-asserted-by":"crossref","first-page":"e49312","DOI":"10.1371\/journal.pone.0049312","article-title":"Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studies","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.028_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MD.0b013e3182943bc2","article-title":"Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies","volume":"92","author":"Bauer","year":"2013","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ejca.2018.06.028_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3945\/ajcn.2010.30009","article-title":"Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) study","volume":"93","author":"Jacobs","year":"2011","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"10.1016\/j.ejca.2018.06.028_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju264","article-title":"Effect of oral bisphosphonates for osteoporosis on development of skeletal metastases in women with breast cancer: results from a pharmaco-epidemiological study","volume":"106","author":"Kremer","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ejca.2018.06.028_bib20","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"20 Pt 2","key":"10.1016\/j.ejca.2018.06.028_bib21","doi-asserted-by":"crossref","first-page":"6222s","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.028_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10585-015-9770-x","article-title":"Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in\u00a0vivo","volume":"33","author":"Holen","year":"2016","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"10.1016\/j.ejca.2018.06.028_bib23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubine","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.ejca.2018.06.028_bib24","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2018.06.028_bib25","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/bcr2769","article-title":"Anti-tumour activity of bisphosphonates in preclinical models of breast cancer","volume":"12","author":"Holen","year":"2010","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2018.06.028_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.06.028_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.ejca.2018.06.028_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918309420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T20:00:33Z","timestamp":1539115233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918309420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":28,"alternative-id":["S0959804918309420"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.06.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}